ISB 1342 is a bispecific monoclonal antibody (bsAb) being studied for the treatment of multiple myeloma in patients who have received prior therapies. ISB 1342 is designed to activate the patient's immune system by redirecting immune cells towards tumor tissue, which may lead to targeted destruction of tumors.
ISB 1342 is able to simultaneously bind to both CD38 and CD3, a protein found on the surface of T-cells. In this way, it can potentially activate T-cells, promoting an immune response against CD38-producing cancer cells that may lead to their targeted killing.
View all active clinical trials around the US.
The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.
The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.
There are no resources, links or videos to display for this treatment.